Biotech Stocks: The Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer

The bloodbath continued for biotech stocks Monday as the J.P. Morgan Healthcare Conference kicked off with massive deals for Pfizer (PFE) and Bayer (BAYRY).




X



Pfizer is teaming up with Beam Therapeutics (BEAM), Codex DNA (DNAY) and Acuitas Therapeutics. The partnerships are around base editing — a new form of gene editing — and messenger RNA. Meanwhile, Bayer said it would partner with Mammoth Biosciences to study gene-editing approaches to liver diseases.

Biotech stocks…

Read More